Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.2 Guidelines


Authors: Owen, D. H.; Singh, N.; Ismaila, N.; Masters, G.; Riely, G. J.; Robinson, A. G.; Schneider, B. J.; Jaiyesimi, I. A.
Title: Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO Living Guideline, version 2023.2
Abstract: Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in theASCO Guidelines Methodology Manual. ASCO Living Guidelines follow theASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found athttps://ascopubs.org/nsclc-da-living-guideline.
Keywords: carcinoma, non-small-cell lung; lung neoplasms; lung tumor; non small cell lung cancer; humans; human
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 24
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-08-20
Start Page: e63
End Page: e72
Language: English
DOI: 10.1200/jco.23.01055
PUBMED: 37433095
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gregory J Riely
    599 Riely